iiinova — where your digital self keeps evolving

The ASCO Post @ascopost.bsky.social · 36m

🖥️ ASCO AI: HemaGuide, a locally deployable LLM agent, turns clinical documentation into treatment recommendations with traceable rationales. Across external validation, it achieved 81.8% concordance with tumor board decisions in hematologic malignancies. ow.ly/q8mE50ZHF5K

000

The ASCO Post @ascopost.bsky.social · 07/10/2026

🖥️ #ASCOAI: Clinical records, imaging, pathology, and molecular profiles generate vast amounts of oncology data, but much remains fragmented. Arsela Prelaj, MD, PhD, discusses how the “Leave No Data Behind” paradigm models could help bring these data together. 🔗 ow.ly/6IMw50ZGG9O

000

The ASCO Post @ascopost.bsky.social · 06/10/2026

💉#ASCOAI: A phase III trial has reported positive results for an individualized neoantigen therapy combo designed with a “deterministic machine learning bioinformatic algorithm.” Intismeran + pembrolizumab improved RFS and DMFS in resected melanoma. 🔗 ow.ly/1nVt50ZHL7W

000

The ASCO Post @ascopost.bsky.social · 05/10/2026

🚹 Nearly 40% of men with Prostate Cancer had newly documented metabolic syndrome within 12 months of starting ADT + ARPI. ➡️ Highlights the importance of early metabolic monitoring 🔹Drs. Amy L. Shaver & Grace Lu-Yao | JAMA Oncology 🔗 ow.ly/x3O950ZGG86

011

The ASCO Post @ascopost.bsky.social · 02/10/2026

🔬 Could immune adaptation contribute to exceptional longevity? Researchers found an expansion of CD4 cytotoxic T cells among supercentenarians, suggesting the immune system may continue adapting in advanced age. ▪️Kosuke Hashimoto, PhD | @cellreports.bsky.social ow.ly/2VyU50ZGG76

000

The ASCO Post @ascopost.bsky.social · 01/10/2026

🩸As survival after Hodgkin Lymphoma improves, long-term health risks remain. New findings highlight cardiovascular disease, secondary cancers, other chronic conditions as priorities for survivorship care. 🔹Drs. Valcarcel & Castillo | JAMA Network Open ow.ly/A4oY50ZGw4v

011

The ASCO Post @ascopost.bsky.social · 30/09/2026

🖥️ One model, 348 diseases. Researchers developed a Bayesian machine learning framework combining longitudinal EHR and genetic data to predict future disease risk and uncover patterns of disease co-occurrence. Read the full article ➡️ ow.ly/FzUx50ZEWsA

021

The ASCO Post @ascopost.bsky.social · 29/09/2026

🥤Daily consumption of sugar-sweetened beverages was associated with an increased risk of developing Gastric Cancer. ➡️ Artificially sweetened beverages were not associated with increased risk ▪️Andrew T. Chan, MD, MPH 🔗 ow.ly/wipF50ZEWro

000

The ASCO Post @ascopost.bsky.social · 28/09/2026

Excess adiposity was linked to a twofold higher risk of vertebral fracture progression in patients with early #BreastCancer receiving aromatase inhibitors. 💪 Higher muscle mass was protective. ▪️Deborah Cosentini, MD | JAMA Network Open 🔗 ow.ly/xl4J50ZEWpX

000

The ASCO Post @ascopost.bsky.social · 25/09/2026

🏘️ The ACS Commission on Cancer has introduced a Rural Cancer Program Accreditation pathway tailored to hospitals in rural counties, aiming to expand access to coordinated, high-quality cancer care closer to home. Learn more 👉 ow.ly/JKZN50Zzxvz

000

The ASCO Post @ascopost.bsky.social · 24/09/2026

📱 A technology-enabled education program nearly tripled skinc ancer screening among HCT survivors, who face elevated long-term risk. ➡️ Outreach to survivors and PCPs could close gaps in cancer survivorship care 🔸Saro Armenian, DO, MPH | JNCCN 🔗 ow.ly/Ck4I50Zzxwn

000

The ASCO Post @ascopost.bsky.social · 23/09/2026

🧬 Decade-long NIH-funded research has created 665 patient-derived tumor models for 25 cancer types. The Human Cancer Models Initiative links models with molecular, clinical data to help researchers study cancer biology & advance precision oncology. 🔗 ow.ly/GzxK50Zzxth

000

The ASCO Post @ascopost.bsky.social · 22/09/2026

🧬A novel HER2-directed antibody-drug conjugate delivered PFS benefit in HER2+ metastatic Breast Cancer In HORIZON-Breast01, trastuzumab rezetecan reduced risk of progression/death by 78% vs pyrotinib + capecitabine. ▪️Erwei Song, MD | The Lancet Oncology 🔗 ow.ly/6wCY50ZyGzw

000

The ASCO Post @ascopost.bsky.social · 21/09/2026

🌏 Nearly 4 in 10 cancer cases worldwide are linked to preventable risk factors. The WHO Global Status Report on Cancer 2026 highlights persistent inequities in prevention, diagnosis, treatment, & supportive care. ➡️ Calls for stronger global action 🔗 ow.ly/IwjN50ZyGAt

000

The ASCO Post @ascopost.bsky.social · 18/09/2026

💻 ASCO AI: MIRA and AMIE move #AI beyond answering clinical questions toward managing episodes of care. Two Nature studies simulating clinical reasoning and patient care suggest agentic AI could support EHR workflows and longitudinal care. 🔗 ow.ly/8jIf50ZwLKB

000

The ASCO Post @ascopost.bsky.social · 17/09/2026

🧬 Ultra low–dose IL-10–expressing CAR T-cell therapy (META 10-19) showed encouraging activity in relapsed/refractory DLBCL, with a 92.3% overall response rate and 84.6% complete remission rate in a phase I trial. ▪️Drs. He Huang & Xingbing Wang | JAMA Oncology ow.ly/buqe50Zxyvg

000

The ASCO Post @ascopost.bsky.social · 16/09/2026

🖥️ Quantum computing may help advance precision #immunooncology. A new quantum machine learning framework (Q-CHIPP) improved prediction of antigen presentation and immunotherapy response vs traditional methods. ▪️Tyler J. Alban, PhD Learn more ➡️ ow.ly/mNEk50ZxyvT

010

The ASCO Post @ascopost.bsky.social · 15/09/2026

🔬Phase 3️⃣ KEYNOTE-B15/EV-304 trial: Perioperative enfortumab vedotin + pembrolizumab improved event-free survival, overall survival, and pathologic complete response vs cisplatin + gemcitabine in muscle-invasive bladder cancer. 🔹 Matthew D. Galsky, MD 🔗 ow.ly/ePbl50ZwLIT

000

The ASCO Post @ascopost.bsky.social · 14/09/2026

🖥️ ASCO AI: From diagnosis to treatment selection and clinical trial matching, AI could support decision-making across the cancer care journey. Experts at ASCOBT 2026 discuss what's needed to make AI work in real-world oncology. Learn more ➡️ ow.ly/ezrQ50ZwAir

000

The ASCO Post @ascopost.bsky.social · 11/09/2026

🖥️ AI may help personalize neoadjuvant treatment for locally advanced rectal cancer. Patients with high tumor cell density had improved survival with irinotecan-intensified chemoradiotherapy vs those with low density. 🔹 Dr. Maria A. Hawkins 🔗 ow.ly/jpVm50ZwLH3

000

The ASCO Post @ascopost.bsky.social · 10/09/2026

💰New American Cancer Society research quantifies the economic burden of cancer in older adults, reinforcing the importance of prevention, early detection, and affordable access to care to reduce both financial hardship and advanced disease costs. Learn more ➡️ ow.ly/K8Ws50ZwLFC

100

The ASCO Post @ascopost.bsky.social · 09/09/2026

💉High-dose chemotherapy then autologous stem cell transplantation improved OS vs nonmyeloablative consolidation in patients with primary CNS lymphoma who responded to MATRix induction. ➡️ Results from phase III MATRix/IELSG43 trial 🔹 Gerald Illerhaus, MD ow.ly/mKfM50ZwAiK

000

The ASCO Post @ascopost.bsky.social · 08/09/2026

💻 #ASCOAI: @anthropicai.bsky.social is making a major push into health care. New initiatives include Claude Science, an #AI platform for scientific research, an internal rare disease drug discovery program, and grants supporting rare disease research. Learn more ➡️ ow.ly/eklU50Ztwg6

000

The ASCO Post @ascopost.bsky.social · 07/09/2026

🏥 How a cancer is diagnosed may matter as much as the diagnosis itself. A new study found patients diagnosed during an emergency department visit had significantly higher mortality across 16 cancer types. ▪️Dr. Georgios Lyratzopoulos 🔗 ow.ly/xvXR50Ztvyv

010

The ASCO Post @ascopost.bsky.social · 04/09/2026

Meta-analysis highlights differences in BTK inhibitor safety with 2nd-generation BTK inhibitors vs ibrutinib: 🔹 Lower risk of atrial fibrillation 🔹 Fewer cardiac events 🔹 Less treatment discontinuation 👨‍⚕️ Moaath Mustafa Ali, MD, MPH ow.ly/AZFu50ZqNFw

000

The ASCO Post @ascopost.bsky.social · 03/09/2026

🏆 Association for Molecular Pathology honored Elaine S. Jaffe, MD, with its 2026 Award for Excellence in Molecular Diagnostics. Her work defining the molecular basis of #ymphomas has influenced decades of clinical practice, research and disease classification. Read more 👉 ow.ly/97t250ZspaN

000

The ASCO Post @ascopost.bsky.social · 02/09/2026

🖥️ ASCO AI: A perfect AI match doesn't guarantee a patient gets on a clinical trial Charles Jiang, MD, examines the real-world workflow, protocol, and operational barriers that continue to limit trial participation. Read the commentary👉 ow.ly/KTRW50ZqNGS

100

The ASCO Post @ascopost.bsky.social · 01/09/2026

🩸 ctDNA continues to show promise as a clinical decision-making tool 🆕 GALAXY data: molecular residual disease status may help identify which patients benefit from adjuvant chemotherapy after resection of colorectal cancer liver metastases. 🔗 ow.ly/MmRk50ZqNEl

010

The ASCO Post @ascopost.bsky.social · 31/08/2026

🌎 Emerging evidence suggests air pollution, tobacco smoke, and pesticide exposure may affect long-term outcomes for childhood cancer survivors. In this interview, Omar Shakeel, MD, details why environmental health should be part of survivorship care. 🔗 ow.ly/7UAi50ZqNCs

021

The ASCO Post @ascopost.bsky.social · 28/08/2026

🖥️ ASCO AI: Machine learning ➕ 3D bioprinting ➕ label-free imaging A new protocol enables high-throughput drug response profiling in tumor organoids, helping identify treatment response patterns that could support precision oncology. Learn more ➡️ ow.ly/YGhM50ZqcS3

021

The ASCO Post @ascopost.bsky.social · 27/08/2026

20-year follow-up from the phase III EORTC 22922/10925 trial found: ➡️ IM-MS nodal irradiation reduced #breastcancer mortality in node-negative disease ➡️ Did not improve non–breast cancer mortality 🔸Philip Poortmans, PhD | The Lancet Oncology Learn more: ow.ly/Kv8v50Zq2v9

010

The ASCO Post @ascopost.bsky.social · 26/08/2026

🤝 The future of AI in dermatology may be collaborative New data found a modern #AI model outperformed less experienced clinicians at diagnosing #SkinCancer but did not outperform expert dermatologists. 🔹Julien Anriot, MD | JAMA Dermatology 🔗 ow.ly/2Uou50Zq2u8

000

The ASCO Post @ascopost.bsky.social · 25/08/2026

🧠 Phase 3️⃣ INTRAGO-II results: Adding intraoperative radiotherapy to surgery did not improve PFS or OS in patients with newly diagnosed glioblastoma, challenging the role of further local dose escalation. 🔹 Frank A. Giordano, MD 🔗 ow.ly/URuy50ZoSch

000

The ASCO Post @ascopost.bsky.social · 24/08/2026

🌎 The latest American Cancer Society Global Cancer Statistics report provides a comprehensive look at cancer incidence, mortality, and trends in 186 countries. The report highlights: ➡️ Rising global burden ➡️ Persistent disparities ➡️ Prevention opportunities ow.ly/eZHc50ZoSbR

000

The ASCO Post @ascopost.bsky.social · 21/08/2026

🖥️ #ASCOAI: New legislation aims to accelerate pediatric cancer research through AI. The AI for Kids With Cancer Act would strengthen data sharing, expand clinical trial access, and support AI innovation to improve outcomes for children with cancer. 🔗 ow.ly/h8hy50ZohKf

020

The ASCO Post @ascopost.bsky.social · 20/08/2026

🫀 Cardio-oncology begins with prevention. A global analysis found smoking and alcohol use were shared modifiable risk factors for both breast cancer and atrial fibrillation/flutter in women aged 55+. 🔹 Shu Wang, MD, PhD Learn more ➡️ ow.ly/5MN250ZohI9

000

The ASCO Post @ascopost.bsky.social · 19/08/2026

🩻 Could some patients with cT1–2N1 Breast Cancer safely receive less radiotherapy? 🔟-year RAPCHEM results found chemo response-guided postoperative RT achieved a 2.9% locoregional recurrence rate. ▪️ Annefleur J.W. Mauritz, MD | The Lancet Oncology 🔗 ow.ly/ZSFP50ZohJ2

000

The ASCO Post @ascopost.bsky.social · 18/08/2026

🚹 Long-term ARTO trial data support metastasis-directed SBRT with systemic therapy in oligometastatic CRPC. Adding SBRT to abiraterone + ADT significantly improved OS and prolonged biochemical & radiologic PFS. 🔸 Giulio Francolini, MD 🔗 ow.ly/T9rQ50ZohGL

010

The ASCO Post @ascopost.bsky.social · 17/08/2026

🎯 Precision testing can open new treatment options in cholangiocarcinoma Phase II eNRGy trial: zenocutuzumab achieved a 36.8% ORR and 57.9% CBR in NRG1+ disease. ▪️ Supported recent #FDA approval. ▪️ James M. Cleary, MD, PhD 🔗 ow.ly/WovT50ZmSKw

001

The ASCO Post @ascopost.bsky.social · 15/08/2026

💻 Can federated learning help unlock the next generation of #AI in oncology? Join Kenneth L. Kehl, MD, MPH, and Umit Topaloglu, PhD, for a live webinar on privacy-preserving AI and collaborative cancer research. 🗓️ Sept. 9 | 6 PM EDT Register: ascoai.broadcastmed.io/live/2/page/5

002

The ASCO Post @ascopost.bsky.social · 14/08/2026

🩻 A breast radiotherapy dosimetry audit of 48 NHS centers found good adherence to heart & lung dose constraints. ➡️ Volumetric-modulated arc therapy improved target coverage but delivered higher mean heart doses. 🔹Anna Kirby, FRCR, MD | The Lancet Oncology ow.ly/NBzq50ZlIHh

000

The ASCO Post @ascopost.bsky.social · 13/08/2026

🚹 Men may be more likely to receive later-stage cancer diagnoses than women. An analysis of 2.4 million U.S. cancer cases found men had higher odds of a regional and/or distant-stage diagnosis across 20 solid tumors. 🔸 Beth Maclin, PhD, MPH 🔗 ow.ly/pLe750ZmSJi

000

The ASCO Post @ascopost.bsky.social · 12/08/2026

🩸 A meta-analysis of 20 studies in non Hodgkin lymphoma and multiple myeloma found second primary malignancies occurred in 3.5% of patients receiving T-cell–engaging bispecific antibodies. 🔹 Roni Shouval, MD, PhD | JAMA Oncology 🔗 ow.ly/R8A050ZlIFc

000

The ASCO Post @ascopost.bsky.social · 11/08/2026

🧠 ASCO AI: Can AI unlock insights even from small datasets? A quantum mechanics–inspired AI framework modeled noisy, high-dimensional multiomic data and identified prognostic markers for neuroblastoma that may also represent future drug targets. 🔗 ow.ly/5zl650ZmSIM

000

The ASCO Post @ascopost.bsky.social · 10/08/2026

🧬 New evidence highlights increased HPV-related cancer risk in select immunosuppressed populations. ➡️ HIV: 4.5-fold higher odds ➡️ Solid organ transplant recipients: 2.2-fold higher odds 🔹 Eva Meglic, MSc | JAMA Network Open Read more 👉 ow.ly/wUnB50ZlICu

000

The ASCO Post @ascopost.bsky.social · 07/08/2026

🖥️ASCOAI: As AI adoption accelerates, the approach to procurement matters. A new framework provides health systems with a practical checklist for evaluating AI vendors, from transparency & bias to implementation & lifecycle management. 🔗 ow.ly/yhc750ZlIAf

000

The ASCO Post @ascopost.bsky.social · 06/08/2026

⏳Long-term FASTRACK II results: stereotactic ablative body #radiotherapy is a safe nonsurgical option for patients with primary kidney cancer. 💯% local control at 7 years 🚫 treatment-related deaths/safety concerns 🔸 Dr. Shankar Siva ow.ly/CE2750ZkQF7

000

The ASCO Post @ascopost.bsky.social · 05/08/2026

🫂 #ASCOAI: Supportive cancer care is about more than treatment. Early findings suggest the AI-based HelpCan91 platform may enable earlier toxicity detection, faster clinician response, & better symptom monitoring for patients with cancer. Learn more ➡️ ow.ly/t42j50ZkQFC

000

The ASCO Post @ascopost.bsky.social · 04/08/2026

🧠 Phase II UNITED trial: MRI-guided adaptive #radiotherapy may improve precision in high-grade glioma. ☑️ 4% marginal failure rate ☑️ Successful margin de-escalation ☑️ Favorable safety profile 👨‍⚕️ Jay Detsky, MD, PhD 🔗 ascopost.com/news/june-2026/mri-gui…

100

The ASCO Post @ascopost.bsky.social · 03/08/2026

🩸 A new risk score may help personalize anticoagulation for cancer-associated venous thromboembolism. The ONCO-DOAC BLEED score stratified major bleeding risk in patients on direct oral anticoagulants. 🔹 Naohiko Nakanishi, MD, PhD | #CardioOncology ow.ly/YN3p50ZkQB1

010